Furanocoumarin metabolites as dietary biomarkers of grapefruit consumption
| ISRCTN | ISRCTN78596053 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN78596053 |
| Secondary identifying numbers | N/A |
- Submission date
- 07/02/2014
- Registration date
- 13/05/2014
- Last edited
- 13/05/2014
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Other
Plain English summary of protocol
Background and study aims
Grapefruit contains high amounts of furanocoumarins, a group of compounds that are known to reduce the activity of intestinal enzymes. As a result, grapefruit juice can interact with a variety of drugs that are taken orally. The aim of this study is to find out whether the breakdown products of furanocoumarin can be used as markers of grapefruit juice consumption.
Who can participate?
Healthy men aged 20-35 years.
What does the study involve?
Participants will be randomly allocated to drink 250 mL of either orange, lemon or grapefruit juice at dinner time. There will then be a 7-day break in which participants are requested to avoid consuming citric-based products. Participants will then repeat this process twice with the second and third juices. Urine samples will be collected the day before the first intervention and in the morning following each intervention.
What are the possible benefits and risks of participating?
The study was conducted according to the Declaration of Helsinki of the World Medical Association. The study was explained to subjects through verbal and written instructions, and written informed consent was obtained before participation.
Where is the study run from?
This study involved the Department of Nutrition and Food Science of the University of Barcelona (Spain).
When is the study starting and how long is it expected to run for?
This study will take place between May 2013 and March 2014.
Who is funding the study?
This study is supported by CIBERobn.
Who is the main contact?
Dr Rosa Lamuela-Raventós
lamuela@ub.edu
Contact information
Scientific
Nutrition and Food Science Department
School of Pharmacy
University of Barcelona
Av. Joan XXIII, s/n
Barcelona
08028
Spain
| Phone | +34 (0) 934 034 843 |
|---|---|
| lamuela@ub.edu |
Study information
| Study design | Open controlled clinical trial |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Other |
| Study type | Other |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | Targeted metabolomics approach for the determination of furanocoumarin metabolites in urine after grapefruit juice consumption |
| Study objectives | Grapefruit contains considerable amounts of furanocoumarins, a family of compounds which are known to strongly inhibit intestinal cytochrome P450 (CYP) enzymes, namely CYP3A4. As a result, grapefruit juice can interact with a variety of orally administered drugs by increasing their bioavailability. This study aims to study the potential of furanocoumarin metabolites as specific biomarkers of grapefruit juice consumption. |
| Ethics approval(s) | Ethics Committee of Clinical Investigation of the University of Barcelona (Spain),18/12/2014, ref: IRB00003099 |
| Health condition(s) or problem(s) studied | Concentration of furanocoumarin metabolites in urine |
| Intervention | Participants are randomly assigned following simple randomization procedures (computerized random numbers) to one of three treatment groups. The study is a randomized crossover feeding trial. Participants will cross over and undergo all three of the interventions. Intervention 1: Administration of 250 mL orange juice. Intervention 2: Administration of 250 mL lemon juice. Intervention 3: Administration of 250 mL grapefruit juice Before each intervention, participants will follow a 7-day washout period, avoiding consuming citric or citric-based products |
| Intervention type | Other |
| Primary outcome measure | Furanocoumarin metabolites will be identified through liquid chromatography coupled to Orbitrap mass spectrometry. Concentrations of furanocoumarins will be determined by liquid chromatography coupled to tandem mass spectrometry (LCMS/MS). These determinations will be carried out in first morning urine samples collected the day before the first intervention and in the morning following each intervention. |
| Secondary outcome measures | N/A |
| Overall study start date | 01/05/2013 |
| Completion date | 01/04/2014 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | Male |
| Target number of participants | 15 |
| Key inclusion criteria | Healthy adult males aged 20-35 years |
| Key exclusion criteria | 1. Previous history of cardiovascular disease (ischemic heart disease - angina or recent or old myocardial infarction, cerebral vascular accident, or peripheral vascular disease) 2. Homeostatic disorders 3. Any several chronic diseases 4. Hypertension or dyslipidemia 5. Smoking subjects 6. Alcoholism 7. Other toxic abuse |
| Date of first enrolment | 01/05/2013 |
| Date of final enrolment | 01/04/2014 |
Locations
Countries of recruitment
- Spain
Study participating centre
08028
Spain
Sponsor information
Research organisation
Centro Hospitalario Universitario de Santiago de Compostela
Edificio "D" 1ª
Planata
Choupana, S/N
Santiago de Compostela
15706
Spain
| gerencia@ciberobn.es | |
| Website | http://www.ciberobn.es/ |
"ROR" |
https://ror.org/02s65tk16 |
Funders
Funder type
Research organisation
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
